The Effects of Frusemide and Probenecid on the Pharmacokinetics of Phenprocoumon

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1990 Jan 1

PMID 2257863

Citations 1

Authors

H Monig

M Bohm

E E Ohnhaus

W Kirch

Affiliations

Soon will be listed here.

Abstract

We have studied the pharmacokinetics of phenprocoumon with and without co-administration of frusemide and probenecid in two groups of 17 healthy volunteers. Frusemide 40 mg b.i.d. for 7 days did not interact with phenprocoumon to a significant extent. Probenecid 500 mg q.i.d. for 7 days significantly accelerated the overall elimination of phenprocoumon, as indicated by a decrease in AUC from 295 to 157 micrograms.h.ml-1, and a reduction in the fraction of the dose excreted by the kidneys. The data are consistent with inhibition of the glucuronidation of phenprocoumon by probenecid. Its accelerated elimination may be a consequence of the increased formation of hydroxylated metabolites.

Citing Articles

Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal.

Macdonald J, Wallace S, Herman R, Verbeeck R Eur J Clin Pharmacol. 1995; 47(6):519-23.

PMID: 7768255 DOI: 10.1007/BF00193705.

References

Boutin J, Thomassin J, Siest G, Batt A . Inhibition studies of microsomal UDP-glucuronosyltransferase activities by furosemide and salicylamide. Pharmacol Res Commun. 1984; 16(3):227-41. DOI: 10.1016/s0031-6989(84)80106-x. View

Welling P, Dean S, Selen A, Kendall M, Wise R . Probenecid: an unexplained effect on cephalosporin pharmacology. Br J Clin Pharmacol. 1979; 8(5):491-5. PMC: 1429805. DOI: 10.1111/j.1365-2125.1979.tb01032.x. View

Veenendaal J, Brooks P, Meffin P . Probenecid-clofibrate interaction. Clin Pharmacol Ther. 1981; 29(3):351-8. DOI: 10.1038/clpt.1981.48. View

Abernethy D, Greenblatt D, Ameer B, Shader R . Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. J Pharmacol Exp Ther. 1985; 234(2):345-9. View

Erttmann R, Damm K . Probenecid and hepatic transport of 3-H-ouabain in rats. Arch Int Pharmacodyn Ther. 1974; 211(2):197-210. View

Meinertz T, Gilfrich H, Groth U, Jonen H, Jahnchen E . Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine. Clin Pharmacol Ther. 1977; 21(6):731-5. DOI: 10.1002/cpt1977216731. View

Smith P, Langendijk P, Bosso J, Benet L . Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac. Clin Pharmacol Ther. 1985; 38(2):121-7. DOI: 10.1038/clpt.1985.146. View

Fishman R . Blood-brain and CSF barriers to penicillin and related organic acids. Arch Neurol. 1966; 15(2):113-24. DOI: 10.1001/archneur.1966.00470140003001. View

Kitteringham N, Bustgens L, Brundert E, Mineshita S, Ohnhaus E . The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. Eur J Clin Pharmacol. 1984; 26(1):65-70. DOI: 10.1007/BF00546711. View

10.

Andreasen F, Husted S . The binding of furosemide to serum proteins in elderly patients: displacing effect of phenprocoumon. Acta Pharmacol Toxicol (Copenh). 1980; 47(3):202-7. DOI: 10.1111/j.1600-0773.1980.tb01560.x. View

11.

VOGIN E, Scott W, Boyd J, Bear W, Mattis P . Effect of probenecid on indocyanine green clearance. J Pharmacol Exp Ther. 1966; 152(3):509-15. View

12.

Ohnhaus E, Berger W, DUCKERT F, Oesch F . The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action. A drug interaction study. Klin Wochenschr. 1983; 61(17):851-8. DOI: 10.1007/BF01537460. View

13.

Heni N, Lehnhardt G, GLOGNER P . [Elimination kinetics of phenprocoumon (Marcumar) in liver cirrhosis and after premedication with phenobarbital]. Int J Clin Pharmacol Biopharm. 1976; 13(4):253-61. View

14.

Aherne G, Piall E, Marks V, Mould G, White W . Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br Med J. 1978; 1(6120):1097-9. PMC: 1604344. DOI: 10.1136/bmj.1.6120.1097. View

15.

HORNBOSTEL H, Kaufmann W, Siegenthaler W . [Drug interactions with coumarins]. Dtsch Med Wochenschr. 1977; 102(10):355-8. View

16.

de Vries J, Zimmermann R, Harenberg J . Phenprocoumon metabolites in human plasma; characterization by HPLC and GC-MS. Eur J Clin Pharmacol. 1986; 29(5):591-4. DOI: 10.1007/BF00635898. View

17.

Harenberg J, Zimmermann R, Staiger C, de Vries J, Walter E, Weber E . Lack of effect of cimetidine on action of phenprocoumon. Eur J Clin Pharmacol. 1982; 23(4):365-7. DOI: 10.1007/BF00613622. View

18.

OReilly R . Phenylbutazone and sulfinpyrazone interaction with oral anticoagulant phenprocoumon. Arch Intern Med. 1982; 142(9):1634-7. View

19.

Upton R, Williams R, Buskin J, Jones R . Effects of probenecid on ketoprofen kinetics. Clin Pharmacol Ther. 1982; 31(6):705-12. DOI: 10.1038/clpt.1982.99. View